Skip to content

Enzyme Activity of Matrix Metalloproteinases in the Serum of Patients With Malignant Obstructive Hyperbilirubinemia Before and After PTBD

Influence of Percutaneous Biliary Drainage on the Change of Enzyme Activity of Matrix Metalloproteinases in the Serum of Patients With Malignant Obstructive Hyperbilirubinemia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04801914
Enrollment
30
Registered
2021-03-17
Start date
2020-12-11
Completion date
2021-05-11
Last updated
2021-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Matrix Metalloproteinase

Keywords

biliary drainage, matrix metalloproteinases

Brief summary

The purpose of this study is to detect differences in the enzymatic activity of matrix metalloproteinases in patients with malignant obstructive hyperbilirubinemia before and after percutaneous biliary drainage.

Detailed description

This study will be designed as a prospective cohort study involving the collection of peripheral blood samples before and one month after percutaneous biliary drainage for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity). Biochemical analyzes are preceded by the entry of data relevant to the research (demographic, anamnestic, clinical and biochemical).

Interventions

Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).

Sponsors

Klinički centar Srbije
CollaboratorUNKNOWN
Institut za Rehabilitaciju Sokobanjska Beograd
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

pathological confirmation or imaging data confirming malignant disease causing bile duct obstruction, performance status 0-1

Exclusion criteria

terminally ill patients, performance status \>2, hepatic decompensation, severe underlying cardiac or renal diseases and coagulation disorders.

Design outcomes

Primary

MeasureTime frameDescription
MMP-2 and MMP-9 serum activityduring interventionMMP serume activity will be measured by molecular biochemical analysis performed on peripheral blood samples taken before and one month after percutaneous biliary drainage

Countries

Serbia

Contacts

Primary ContactAleksandar N Filipovic, Dr
aleksandar.filipovic11@gmail.com+381658832505

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026